Our findings suggest that KLF2 may inhibit tumor angiogenesis and growth in breast cancer by inhibiting the VEGFA-HIF pathway, and thus KLF2 may be an important anti-angiogenesis therapeutic target for breast cancer. The gene discussed is KLF2; the disease is breast cancer.